Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 636

Results For "RAT"

6686 News Found

Labcorp, a leader in women’s heath solutions acquires Ovia Health
Digitisation | August 13, 2021

Labcorp, a leader in women’s heath solutions acquires Ovia Health

The transaction improves patient experience, patient outcomes and aims to reduce health care costs


JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
News | August 13, 2021

JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22

Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21


HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Healthcare | August 13, 2021

HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY

Substantial reduction in losses


Mangalam Drugs signs tech transfer agreement with Nigerian pharma company
News | August 12, 2021

Mangalam Drugs signs tech transfer agreement with Nigerian pharma company

Anti-malaria API facility will be operational in 15-18 months


Cipla receives USFDA approval for Difluprednate Ophthalmic Emulsion 0.05%
Drug Approval | August 12, 2021

Cipla receives USFDA approval for Difluprednate Ophthalmic Emulsion 0.05%

It’s an AB-rated generic therapeutic version of Durezol


Indian pharma market grew by 13.7% in July 2021: Ind-Ra
News | August 12, 2021

Indian pharma market grew by 13.7% in July 2021: Ind-Ra

Demand normalisation post the second wave contributed to the steady growth


Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
Drug Approval | August 12, 2021

Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness

A treatment to prevent extreme symptoms and cut hospitalisation


Global cell expansion market poised for huge growth
Biotech | August 12, 2021

Global cell expansion market poised for huge growth

Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030


SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
Drug Approval | August 12, 2021

SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants

SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial


Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee
Drug Approval | August 12, 2021

Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee

The company is eligible for 12 months exclusivity from launch